AS-LRRK2 & AS-SYN Series Version 2.8.0: Multi-Vector Parkinson's Disease Platform (2026) — De Novo LRRK2 G2019S Kinase Inhibitors (AS-LRRK2-006B-DualD4, AS-LRRK2-Pyr-Spiro-v2, AS-LRRK2-006A-DualD4), First-in-Class Alpha-Synuclein Oligomerization Inhibitors (AS-SYN-003 & AS-SYN-007-TriOCD3), Two-Layer Selectivity Paradigm (240x-431x in silico vs 20x-50x cellular), and Independent SIB SwissADME Audit
- DOI
- 10.5281/zenodo.23526889
- Published
- 2026
- Container
- Not recorded
- Publisher
- Zenodo
- Open access
- yes
Credibility signals
limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.5281/zenodo.23526889,
title = {AS-LRRK2 \& AS-SYN Series Version 2.8.0: Multi-Vector Parkinson's Disease Platform (2026) — De Novo LRRK2 G2019S Kinase Inhibitors (AS-LRRK2-006B-DualD4, AS-LRRK2-Pyr-Spiro-v2, AS-LRRK2-006A-DualD4), First-in-Class Alpha-Synuclein Oligomerization Inhibitors (AS-SYN-003 \& AS-SYN-007-TriOCD3), Two-Layer Selectivity Paradigm (240x-431x in silico vs 20x-50x cellular), and Independent SIB SwissADME Audit},
author = {Sokolov, Artyom},
year = {2026},
doi = {10.5281/zenodo.23526889},
url = {https://doi.org/10.5281/zenodo.23526889}
}RIS
TY - JOUR TI - AS-LRRK2 & AS-SYN Series Version 2.8.0: Multi-Vector Parkinson's Disease Platform (2026) — De Novo LRRK2 G2019S Kinase Inhibitors (AS-LRRK2-006B-DualD4, AS-LRRK2-Pyr-Spiro-v2, AS-LRRK2-006A-DualD4), First-in-Class Alpha-Synuclein Oligomerization Inhibitors (AS-SYN-003 & AS-SYN-007-TriOCD3), Two-Layer Selectivity Paradigm (240x-431x in silico vs 20x-50x cellular), and Independent SIB SwissADME Audit AU - Sokolov, Artyom PY - 2026 DO - 10.5281/zenodo.23526889 UR - https://doi.org/10.5281/zenodo.23526889 ER -
APA
Artyom, S. (2026). AS-LRRK2 & AS-SYN Series Version 2.8.0: Multi-Vector Parkinson's Disease Platform (2026) — De Novo LRRK2 G2019S Kinase Inhibitors (AS-LRRK2-006B-DualD4, AS-LRRK2-Pyr-Spiro-v2, AS-LRRK2-006A-DualD4), First-in-Class Alpha-Synuclein Oligomerization Inhibitors (AS-SYN-003 & AS-SYN-007-TriOCD3), Two-Layer Selectivity Paradigm (240x-431x in silico vs 20x-50x cellular), and Independent SIB SwissADME Audit. https://doi.org/10.5281/zenodo.23526889